Pharmacokinetics and Bioequivalence of Mirogabalin Orally Disintegrating Tablets and Conventional Tablets in Healthy Japanese Participants

• Published in: Clinical pharmacology in drug development Vol. 12; no. 10; pp. 985 - 990
• Main Authors: Toyama, Kaoru, Eto, Takashi, Suzuki, Kanae, Shinohara, Sayaka, Yoshiba, Satoshi, Yoshihara, Kazutaka, Ishizuka, Hitoshi
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2023
• Subjects: Bioequivalence; Plasma; orally disintegrating tablet; mirogabalin; neuropathic pain; bioequivalence
• ISSN: 2160-763X; 2160-7648; 2160-7648
• DOI: 10.1002/cpdd.1292

This single‐center, randomized, open‐label, single‐dose, 2‐group, 2‐stage crossover trial evaluated the bioequivalence of 15 mg of mirogabalin as orally disintegrating tablets (ODTs) with conventional mirogabalin tablets in healthy Japanese men. The trial involved two studies: in Study 1, the ODT formulation was taken without water, and in Study 2, the ODT formulation was taken with water. The conventional tablet was taken with water in both studies. We investigated the pharmacokinetic parameters and bioequivalence of the 2 formulations, including the maximum plasma concentration and the area under the plasma concentration‐time curve up to the last quantifiable time. The plasma concentrations of mirogabalin were determined by a validated liquid chromatography with tandem mass spectrometry method. A total of 72 participants were enrolled and completed the trial. The geometric least‐squares mean ratios of maximum plasma concentration of the ODT formulation to the conventional formulation were within the prespecified bioequivalence range of 0.80–1.25 (Study 1, 0.995; Study 2, 1.009), as was the area under the plasma concentration‐time curve up to the last quantifiable time (Study 1, 1.023; Study 2, 1.035). No serious adverse events were observed. In conclusion, mirogabalin 15‐mg ODTs, either with or without water, were bioequivalent to conventional 15‐mg tablets.